Antibodies News and Research

RSS

MPL vaccine can stimulate brain's natural defense mechanisms in people with AD

A team of researchers from Universit- Laval, CHU de Qu-bec, and pharmaceutical firm GlaxoSmithKline (GSK) has discovered a way to stimulate the brain's natural defense mechanisms in people with Alzheimer's disease.

17 Jan 2013

New menu of 61 genetically engineered E. coli strains may improve efficacy of vaccines

Researchers at The University of Texas at Austin have developed a menu of 61 new strains of genetically engineered bacteria that may improve the efficacy of vaccines for diseases such as flu, pertussis, cholera and HPV.

17 Jan 2013

UCLA, NanoSmart partner to develop novel cancer drug delivery platform

NanoSmart Pharmaceuticals, a private biotechnology company, has entered into a research collaboration agreement with University of California Los Angeles (UCLA) to continue the development of NanoSmart's novel drug delivery platform for the treatment of cancer and other life-threatening diseases.

17 Jan 2013

Protein Sciences receives FDA approval for Flublok vaccine

The U.S. Food and Drug Administration today announced that it has approved Flublok, the first trivalent influenza vaccine made using an insect virus (baculovirus) expression system and recombinant DNA technology. Flublok is approved for the prevention of seasonal influenza in people 18 through 49 years of age.

16 Jan 2013

New initiative aims to accelerate biomarker search in Parkinson's

A new initiative aims to accelerate the search for biomarkers - changes in the body that can be used to predict, diagnose or monitor a disease - in Parkinson's disease, in part by improving collaboration among researchers and helping patients get involved in clinical studies.

16 Jan 2013

Elan, Biogen Idec submit applications to FDA and EMA for updation of TYSABRI labels

Today Biogen Idec and Elan Corporation, plc announced that they have submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) requesting updates to the TYSABRI (natalizumab) labels.

16 Jan 2013

Experimental vaccine elicits antibodies that can protect against Ebola virus infection

Researchers at the National Institutes of Health (NIH) and Oregon Health & Science University (OHSU) have found that an experimental vaccine elicits antibodies that can protect nonhuman primates from Ebola virus infection.

16 Jan 2013

GeneTex to introduce new EasyBlot reagent

GeneTex, a leading manufacturer of high-quality antibodies, is pleased to announce that they will be launching EasyBlot, a new secondary antibody reagent that eliminates the interference that has long plagued immunoprecipitation (IP) experiments when the IP and western blot primary antibodies are from the same host.

16 Jan 2013

Early hepatitis B vaccination may be ineffective in teenagers

Research reveals that many infants who receive the complete series of hepatitis B virus vaccinations have lost their protection by the time they reach adolescence.

14 Jan 2013

Additional insights into workings of ALVAC vaccine against HIV

Four years ago, a potential HIV vaccine showed promise against the virus that causes AIDS, but it fell short of providing the broad protection necessary to stem the spread of disease.

11 Jan 2013

Scientists develop playbook to end devastating impact of fibrotic diseases

A team of scientists has developed a playbook for ending the devastating impact of fibrotic diseases of the liver, lung, kidney, and other organs, which are responsible for as many as 45 percent of all deaths in the industrialized world.

11 Jan 2013

TSRI chemists develop new cell-marking method

Chemists at The Scripps Research Institute (TSRI) have found an easier way to perform one of the most fundamental tasks in molecular biology. Their new method allows scientists to add a marker to certain cells, so that these cells may be easily located and/or selected out from a larger cell population.

10 Jan 2013

Prion filtration tested for red blood cell transfusions

Red blood cell prion filtration does not increase the risk for alloimmunization or transfusion reactions, suggest results from the largest safety study to date.

9 Jan 2013

Adolescents may lose hepatitis B virus protection despite vaccination as infants

New research reveals that a significant number of adolescents lose their protection from hepatitis B virus (HBV) infection, despite having received a complete vaccination series as infants. Results in the January 2013 issue of Hepatology, a journal published by Wiley on behalf of the American Association for the Study of Liver Diseases, suggest teens with high-risk mothers (those positive for HBeAg) and teens whose immune system fails to remember a previous viral exposure (immunological memory) are behind HBV reinfection.

8 Jan 2013

Seven scientists named 2013 recipients of Damon Runyon-Rachleff Innovation Award

The Damon Runyon Cancer Research Foundation announced that seven scientists with novel approaches to fighting cancer have been named 2013 recipients of the Damon Runyon-Rachleff Innovation Award.

8 Jan 2013

arGEN-X commences ARGX-110 Phase Ib trial to treat cancer

arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announced today the initiation of a Phase Ib first-in-man cancer study with ARGX-110, its first SIMPLE Antibody program to enter the clinic in just three years from initiation of discovery.

7 Jan 2013